Literature DB >> 20129550

Second-generation drug-eluting stents and the continuous need for rapidly available real-world data.

Debabrata Mukherjee, David J Moliterno.   

Abstract

Mesh:

Substances:

Year:  2009        PMID: 20129550     DOI: 10.1016/j.jcin.2009.10.010

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


× No keyword cloud information.
  6 in total

1.  Comparing clinical outcomes for a twelve-month trial of zotarolimus- and everolimus-eluting stents in patients with coronary artery disease: data from the THCRIC registry.

Authors:  Hamid Reza Poorhoseini; Seyed Ebrahim Kassaian; Kianoosh Hoseini; Sepideh Saroukhani; Mojtaba Salarifar; Mohammad Alidoosti; Ebrahim Nematipour; Ali Mohammad Haji-Zeinali; Alireza Amirzadegan; Mir Hossein Seyyed Mohammadzadeh; Kamal Khadem Vatan; Hassan Aghajani; Mahmood Sheikh Fathollahi; Hamidreza Farrokh-Eslamlou
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-02-07

Review 2.  [Second-generation DES : New, but also cost-effective?].

Authors:  F Müller-Riemenschneider; T Reinhold; S N Willich
Journal:  Herz       Date:  2011-05       Impact factor: 1.443

3.  Clinical impact of routine follow-up coronary angiography after second- or third-generation drug-eluting stent insertion in clinically stable patients.

Authors:  Seonghoon Choi; Hee-Sun Mun; Min-Kyung Kang; Jung Rae Cho; Seong Woo Han; Namho Lee
Journal:  Korean J Intern Med       Date:  2014-12-30       Impact factor: 2.884

4.  TWENTE Study: The Real-World Endeavor Resolute Versus Xience V Drug-Eluting Stent Study in Twente: study design, rationale and objectives.

Authors:  M W Z Basalus; K Tandjung; K G van Houwelingen; M G Stoel; F H A F de Man; J W Louwerenburg; S A M Saïd; G C M Linssen; M A W J Kleijne; J van der Palen; J Huisman; P M J Verhorst; C von Birgelen
Journal:  Neth Heart J       Date:  2010-08       Impact factor: 2.380

5.  A Randomized Comparison between Everolimus-Eluting Stent and Cobalt Chromium Stent in Patients with Acute ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention Using Routine Intravenous Eptifibatide: The X-MAN (Xience vs. Multi-Link Stent in Acute Myocardial Infarction) Trial, A Pilot Study.

Authors:  Surya Dharma; Alexander J Wardeh; Sunarya Soerianata; Isman Firdaus; J Wouter Jukema
Journal:  Int J Angiol       Date:  2014-06

6.  Comparison of optical coherence tomographic assessment between first- and second-generation drug-eluting stents.

Authors:  Byeong-Keuk Kim; Jung-Sun Kim; Junbeom Park; Young-Guk Ko; Donghoon Choi; Yangsoo Jang; Myeong-Ki Hong
Journal:  Yonsei Med J       Date:  2012-05       Impact factor: 2.759

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.